Adenomas of the pars intermedia from 19 horses and normal pituitary glands from seven horses were evaluated histologically and immunocytochemically for adrenocorticotropic hormone (ACTH), α-mela-nocyte-stimulating hormone (α-MSH), β-endorphin (β-END), proopiomelanocortin (POMC), prolactin, neuron specific enolase, and glial fibrillary acidic protein (GFAP). The 26 horses ranged in age from 7 to 31 years. Histologically, all adenomas had a uniform pattern characterized by cords of large columnar cells forming palisades and pseudoacini separated by a delicate fibrovascular stroma. Immunostaining of adenomas derived from the pars intermedia was similar to that of non-neoplastic equine pars intermedia. An immunocytochemical evaluation revealed a diffuse, strong cytoplasmic reaction for POMC, a moderate to strong reaction for α-MSH and β-END, a weak reaction for ACTH, and negative immunostaining for prolactin, GFAP, and neuron specific enolase in the adenomas. The unique clinicopathologic syndrome that develops in horses with pituitary adenomas appears to be the result of an over-production of POMC-derived peptides in addition to space-occupying effects resulting in dysfunction of the hypothalamus and neurohypophysis.
AsaSLKovacsKValeWPetruszPVecseiP:
Immunohistologic localization of corticotrophin-releasing hormone in human tumors.
Am J Clin Pathol87:
327–333,
1987
2.
BakerJRRitchieHE:
Diabetes mellitus in the horse: a case report and review of the literature.
Equine Vet J6:
7–11,
1974
3.
BlähserSHeinrichsM:
Immunoreactive neuropeptide systems in avian embryos (domestic mallard, domestic fowl, Japanese quail).
Cell Tissue Res223:
287–303,
1982
4.
ChenCLNeilsonJTMKumarMSAEstesKS:
Isolation and partial characterization of prolactin from equine pituitary gland (hypophysis).
Am J Vet Res40:
1303–1306,
1979
5.
ChrétienMSeidahNG:
Chemistry and biosynthesis of pro-opiomelanocortin.
Mol Cell Biochem34:
101–127,
1981
6.
DavisMD:
The hypothalamo-hypophyseal rat explant in vitro: endocrinological studies of the pars intermedia dopaminergic neural input.
J Physiol (Lond)370:
381–393,
1986
7.
DeLellisRADayalYTischlerASLeeAKWolfeHJ:
Multiple endocrine neoplasia (MEN) syndromes: cellular origins and interrelationships.
Int Rev Exp Pathol28:
163–215,
1986
8.
EipperBAMainsRE:
Structure and biosynthesis of pro-adrenocortico-tropin/endorphin and related peptides.
Endocr Rev1:
1–27,
1980
GribbleDH:
The endocrine system.
In:
Equine Medicine & Surgery,
ed. CatcottEJSmithcorsJF,
2nd ed.,
pp. 433–457.
American Veterinary Publications,
Wheaton, IL,
1972
11.
KovacsKHorvathE:
Pathology of pituitary tumors.
Endocrinol Metab Clin North Am16:
529–551,
1987
12.
KriegerDT:
Physiopathology of Cushing's disease.
Endocr Rev4:
22–43,
1983
13.
LeeAKDeLellisRABlountMNunnemacherGWolfeHJ:
Pituitary proliferative lesions in aging male Long-Evans rats. A model of mixed multiple endocrine neoplasia syndrome.
Lab Invest47:
595–602,
1982
14.
LloydRVChandlerWFMcKeeverPESchteingartDE:
The spectrum of ACTH-producing pituitary lesions.
Am J Surg Pathol10:
618–626,
1986
15.
LoebWFCapenCCJohnsonLE:
Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses.
Cornell Vet56:
623–639,
1966
McNicolAMKubbaMAGMcTeagueE:
The mitogenic effects of corticotrophin-releasing factor on the anterior pituitary gland of the rat.
J Endocrinol118:
237–241,
1988
19.
MillingtonWRDybdalNODawsonRJrManziniCMuellerGP:
Equine Cushing's disease: differential regulation of β-endorphin processing in tumors of the intermediate pituitary.
Endocrinology123:
1598–1604,
1988
20.
MooreJNSteissJNicholsonWEOrthDN:
A case of pituitary adrenocorticotropin-dependent Cushing's disease in the horse.
Endocrinology104:
576–582,
1979
21.
OrthDNHolscherMAWilsonMGNicholsonWEPlueREMountCD:
Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests.
Endocrinology110:
1430–1441,
1982
22.
OrthDNNicholsonWE:
Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease.
Endocrinology111:
559–563,
1982
23.
PauliBURossiGLStraubR:
Zwischenzelladenom der Hypophyse mit “Cushing-ähnlicher” Symptomatologie beim Pferd.
Vet Pathol11:
417–429,
1974
24.
PetersonMEOrthDNHalmiNSZielinksiACDavisDRChavezFTDruckerWD:
Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations.
Endocrinology119:
720–730,
1986
25.
RivierCLPlotskyPM:
Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion.
Ann Rev Physiol48:
475–494,
1986
26.
SalandLCGutierrezLKranerJSamoraA:
Corticotropin-releasing factor (CRF) and neurotransmitters modulate melanotropic peptide release from rat neurointermediate pituitary in vitro.
Neuropeptides12:
59–66,
1988
27.
SegerMABennettHPJ:
Structure and bioactivity of the amino-terminal fragment of pro-opiomelanocortin.
J Steroid Biochem25:
703–710,
1986
28.
SippleJH:
The association of pheochromocytoma with carcinoma of the thyroid gland.
Am J Med31:
163–166,
1961
29.
SternbergerLA:
Immunocytochemistry,
3rd ed.,
pp. 1–524.
Wiley and Sons,
New York, NY,
1986
30.
SuzukiHMohrUKimmerleG:
Spontaneous endocrine tumors in Sprague-Dawley rats.
J Cancer Res Clin Oncol95:
187–196,
1979
31.
VermesIMulderGHSmelikPGTildersFJH:
Differential control of β-endorphin/β-lipotropin secretion from anterior and intermediate lobes of the rat pituitary gland in vitro.
Life Sci27:
1761–1768,
1980
32.
WermerP:
Genetic aspects of adenomatosis of endocrine glands.
Am J Med16:
363–371,
1954
33.
WilsonMGNicholsonWEHolscherMASherrellBJMountCDOrthDN:
Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.
Endocrinology110:
941–954,
1982
34.
WilsonRBHolscherMAKasselbergAGJonesM:
Leu-enkephalin and somatostatin immunoreactivities in canine and equine pheochromocytomas.
Vet Pathol23:
96–98,
1986
